Nektar Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Nektar Therapeutics (NKTR) Tops Q4 EPS by 2c
February 28, 2022 4:35 PM ESTNektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.79), $0.02 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $25 million versus the consensus estimate of $25.33 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
... More